CliffBio
biologic

Jivi

Antihemophilic factor (recombinant), PEGylated-aucl

Loss of exclusivityDecember 2036projected — 12-year biologic exclusivity estimate
CompanyBayer Healthcare →View the full company profile on CliffBio

Drug detail

Brand nameJivi
Active ingredientAntihemophilic factor (recombinant), PEGylated-aucl
Strength4000IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalDecember 2024
Marketing statusRx

More from Bayer Healthcare

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Jivi patent cliff — loss of exclusivity December 2036 | CliffBio